Innate Pharma and MedImmune enter clinical trial collaboration
Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board
World renowned immunologist, professor Eric Vivier, joins Innate Pharma as Chief Scientific Officer
Number of shares and voting rights of Innate Pharma as at January 1, 2018
Upcoming investor conferences
Innate Pharma announces its financial calendar for 2018
Number of shares and voting rights of Innate Pharma as at december 4, 2017
Innate Pharma provides an update on Lirilumab
Third quarter 2017 report
Final results of the dose-escalation part from the phase I trial evaluating IPH4102 in patients with advanced cutaneous T-cell lymphomas presented at the EORTC CLTF meeting
